Peanut Allergy – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Peanut Allergy – Pipeline Review, H1 2018’, provides an overview of the Peanut Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Peanut Allergy

– The report reviews pipeline therapeutics for Peanut Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Peanut Allergy therapeutics and enlists all their major and minor projects

– The report assesses Peanut Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Peanut Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Peanut Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adverum Biotechnologies Inc

Aimmune Therapeutics Inc

Alfacyte Ltd

Allergy Therapeutics Plc

AnaptysBio Inc

ASIT Biotech SA

Astellas Pharma Inc

BioLingus AG

Cambridge Allergy Ltd

DBV Technologies SA

HAL Allergy BV

Intrommune Therapeutics

Regeneron Pharmaceuticals Inc

Sanofi

Selecta Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peanut Allergy Overview

Peanut Allergy Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peanut Allergy Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peanut Allergy Companies Involved in Therapeutics Development

Adverum Biotechnologies Inc

Aimmune Therapeutics Inc

Alfacyte Ltd

Allergy Therapeutics Plc

AnaptysBio Inc

ASIT Biotech SA

Astellas Pharma Inc

BioLingus AG

Cambridge Allergy Ltd

DBV Technologies SA

HAL Allergy BV

Intrommune Therapeutics

Regeneron Pharmaceuticals Inc

Sanofi

Selecta Biosciences Inc

Peanut Allergy Drug Profiles

aldesleukin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANB-020 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANN-004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0892 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBV-712 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HALMPE-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyvac Peanut Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-108 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-439794 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-204 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTC-064 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peanut Allergy Dormant Projects

Peanut Allergy Discontinued Products

Peanut Allergy Product Development Milestones

Featured News & Press Releases

Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO

Feb 28, 2018: Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac Peanut allergy product

Feb 27, 2018: Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results at the AAAAI-WAO Joint Congress

Feb 20, 2018: Aimmune Therapeutics Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients with Peanut Allergy

Feb 14, 2018: DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut

Feb 12, 2018: Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress

Feb 12, 2018: DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint Congress

Jan 10, 2018: Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy

Jan 08, 2018: Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy

Nov 20, 2017: Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1

Nov 20, 2017: DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients

Nov 14, 2017: DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association

Oct 31, 2017: Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial

Oct 21, 2017: Statement from Camallergy on the results from DBV Technologies of their phase 3 trial of Viaskin skin patch for peanut allergy which has failed

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Peanut Allergy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Peanut Allergy Pipeline by Adverum Biotechnologies Inc, H1 2018

Peanut Allergy Pipeline by Aimmune Therapeutics Inc, H1 2018

Peanut Allergy Pipeline by Alfacyte Ltd, H1 2018

Peanut Allergy Pipeline by Allergy Therapeutics Plc, H1 2018

Peanut Allergy Pipeline by AnaptysBio Inc, H1 2018

Peanut Allergy Pipeline by ASIT Biotech SA, H1 2018

Peanut Allergy Pipeline by Astellas Pharma Inc, H1 2018

Peanut Allergy Pipeline by BioLingus AG, H1 2018

Peanut Allergy Pipeline by Cambridge Allergy Ltd, H1 2018

Peanut Allergy Pipeline by DBV Technologies SA, H1 2018

Peanut Allergy Pipeline by HAL Allergy BV, H1 2018

Peanut Allergy Pipeline by Intrommune Therapeutics, H1 2018

Peanut Allergy Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Peanut Allergy Pipeline by Sanofi, H1 2018

Peanut Allergy Pipeline by Selecta Biosciences Inc, H1 2018

Peanut Allergy Dormant Projects, H1 2018

Peanut Allergy Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Peanut Allergy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports